Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class, masked, ...
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its ...
Future Market Insights10h
Global PD-1/PD-L1 Inhibitors Market Set to Reach USD 123.3 Billion by 2033, Growing at a 9.6% CAGR
The global PD-1/PD-L1 inhibitors market is projected to witness remarkable growth over the next decade, with an estimated ...
ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has entered into a ...